Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

126 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Target trial emulation to evaluate the effect of immune-related adverse events on outcomes in metastatic urothelial cancer.
Pichler R, Fritz J, Maier S, Hassler MR, Krauter J, D Andrea D, Laukhtina E, Gust K, Mori K, Tully KH, Niedersuess-Beke D, Korber L, Spiegelberg JA, Bauernhofer T, Subiela JD, Mayr R, Kronbichler A, Moschini M, Teoh J, Pradere B, Shariat SF, Ulmer H, Mertens LS; European Association of Urology–Young Academic Urologists (EAU-YAU): Urothelial Carcinoma Working Group. Pichler R, et al. Among authors: mertens ls. Cancer Immunol Immunother. 2024 Dec 21;74(1):30. doi: 10.1007/s00262-024-03871-7. Cancer Immunol Immunother. 2024. PMID: 39708183 Free PMC article.
Stage-dependent survival in patients treated with neoadjuvant chemotherapy and radical cystectomy.
D'Andrea D, Shariat SF, Soria F, DI Trapani E, Mertens LS, VAN Rhijn BW, Dinney CP, Black PC, Spiess PE, Carrion DM, Pradere B, Tonin E, Pichler R, Filippot R, Mari A, Moschini M; European Association of Urology-Young Academic Urologists (EAU-YAU): Urothelial Carcinoma Working Group. D'Andrea D, et al. Among authors: mertens ls. Minerva Urol Nephrol. 2023 Aug;75(4):452-459. doi: 10.23736/S2724-6051.23.05289-8. Epub 2023 Jun 14. Minerva Urol Nephrol. 2023. PMID: 37314813 Free article.
Intravesical BCG in bladder cancer induces innate immune responses against SARS-CoV-2.
Pichler R, Diem G, Hackl H, Koutník J, Mertens LS, D Andrea D, Pradere B, Soria F, Mari A, Laukhtina E, Krajewski W, Teoh JY, Del Guidice F, Moschini M, Thurnher M, Posch W. Pichler R, et al. Among authors: mertens ls. Front Immunol. 2023 Jul 13;14:1202157. doi: 10.3389/fimmu.2023.1202157. eCollection 2023. Front Immunol. 2023. PMID: 37520557 Free PMC article.
Prognosis of patients with T1 low-grade urothelial bladder cancer treated with bacillus Calmette-Guérin immunotherapy.
Piszczek R, Krajewski W, Subiela JD, Del Giudice F, Nowak Ł, Chorbińska J, Moschini M, Masson-Lecomte A, Bebane S, Cimadamore A, Grobet-Jeandin E, Rouprêt M, D'Andrea D, Mastroianni R, Gutierrez Hidalgo B, Gomez Rivas J, Mori K, Soria F, Laukhtina E, Mari A, Albisinni S, Gallioli A, Mertens LS, Pichler R, Marcq G, Łaszkiewicz J, Hałoń A, Carrion DM, Akand M, Pradere B, Shariat SF, Palou J, Babjuk M, Burgos Revilla J, Małkiewicz B, Szydełko T; European Association of Urology EAU-Young Academic Urologists YAU Urothelial Cancer Working Party. Piszczek R, et al. Among authors: mertens ls. Minerva Urol Nephrol. 2023 Oct;75(5):591-599. doi: 10.23736/S2724-6051.23.05418-6. Minerva Urol Nephrol. 2023. PMID: 37728495 Free article.
Impact of the extent of lymph node dissection on survival outcomes in clinically lymph node-positive bladder cancer.
von Deimling M, Furrer M, Mertens LS, Mari A, van Ginkel N, Bacchiani M, Maas M, Pichler R, Li R, Moschini M, Bianchi A, Vetterlein MW, Lonati C, Crocetto F, Taylor J, Tully KH, Afferi L, Soria F, Del Giudice F, Longoni M, Laukhtina E, Antonelli A, Rink M, Fisch M, Lotan Y, Spiess PE, Black PC, Kiss B, Pradere B, Shariat SF; CLIPOLY Study Group Collaborators. von Deimling M, et al. Among authors: mertens ls. BJU Int. 2024 Mar;133(3):341-350. doi: 10.1111/bju.16210. Epub 2023 Nov 15. BJU Int. 2024. PMID: 37904652
Unlocking the Potential of Adequate Bacillus Calmette-Guérin Immunotherapy in Very-high-risk Non-muscle-invasive Bladder Carcinoma: A Multicenter Analysis of Oncological Outcomes and Risk Dynamics.
Subiela JD, Krajewski W, González-Padilla DA, Laszkiewicz J, Taborda J, Aumatell J, Sanchez Encinas M, Basile G, Moschini M, Caño-Velasco J, Lopez Perez E, Del Olmo Durán P, Gallioli A, Tukiendorf A, D'Andrea D, Yuen-Chun Teoh J, Serna Céspedes A, Pichler R, Afferi L, Del Giudice F, Gomez Rivas J, Albisinni S, Soria F, Ploussard G, Mertens LS, Rajwa P, Laukhtina E, Pradere B, Tully K, Guerrero-Ramos F, Rodríguez-Faba Ó, Alvarez-Maestro M, Dominguez-Escrig JL, Szydełko T, Gomez Dos Santos V, Jiménez Cidre MÁ, Burgos Revilla FJ; European Association of Urology-Young Academic Urologists EAU-YAU: Urothelial Carcinoma Working Group. Subiela JD, et al. Among authors: mertens ls. Eur Urol Oncol. 2024 Dec;7(6):1367-1375. doi: 10.1016/j.euo.2024.01.017. Epub 2024 Feb 13. Eur Urol Oncol. 2024. PMID: 38355375
The optimal number of induction chemotherapy cycles in clinically lymph node-positive bladder cancer.
von Deimling M, Mertens LS, Furrer M, Li R, Tendijck GAH, Taylor J, Crocetto F, Maas M, Mari A, Pichler R, Moschini M, Tully KH, D'Andrea D, Laukhtina E, Del Giudice F, Marcq G, Velev M, Gallioli A, Albisinni S, Mori K, Khanna A, Rink M, Fisch M, Minervini A, Black PC, Lotan Y, Spiess PE, Kiss B, Shariat SF, Pradere B; CLIPOLY Study Group Collaborators. von Deimling M, et al. Among authors: mertens ls. BJU Int. 2024 Jul;134(1):119-127. doi: 10.1111/bju.16319. Epub 2024 Mar 12. BJU Int. 2024. PMID: 38470089 Free article.
The Role of Mitomycin C in Intermediate-risk Non-muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis.
Scilipoti P, Ślusarczyk A, de Angelis M, Soria F, Pradere B, Krajewski W, D'Andrea D, Mari A, Giudice FD, Pichler R, Subiela JD, Afferi L, Albisinni S, Mertens L, Laukhtina E, Mori K, Radziszewski P, Shariat SF, Necchi A, Xylinas E, Gontero P, Rouprêt M, Montorsi F, Briganti A, Moschini M; European Association of Urology Young Academic Urologists Urothelial Carcinoma Working Group. Scilipoti P, et al. Eur Urol Oncol. 2024 Dec;7(6):1293-1302. doi: 10.1016/j.euo.2024.06.005. Epub 2024 Jun 19. Eur Urol Oncol. 2024. PMID: 38902138 Review.
Clinical Validation of the Intermediate-risk Non-muscle-invasive Bladder Cancer Scoring System and Substratification Model Proposed by the International Bladder Cancer Group: A Multicenter Young Academic Urologists Urothelial Working Group Collaboration.
Soria F, Rosazza M, Livoti S, Moschini M, De Angelis M, Giudice FD, Pichler R, Hurle R, Mancon S, Carrion DM, Krajewski W, Mertens LS, D'Andrea D, Mari A, Di Maida F, Dutto D, Colucci F, Casale G, Fertitta G, Laukhtina E, Albisinni S, Pradere B, Teoh JYC, Shariat SF, Briganti A, Kamat AM, Gontero P. Soria F, et al. Among authors: mertens ls. Eur Urol Oncol. 2024 Dec;7(6):1497-1503. doi: 10.1016/j.euo.2024.06.004. Epub 2024 Jun 20. Eur Urol Oncol. 2024. PMID: 38906794 Free article.
126 results